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delivery into solid tumors.[1] This is espe-
cially true for nucleic acid-based therapeu-
tics, where tumor delivery and endosomal 
escape of oligonucleotides are particu-
larly challenging. The enhanced perme-
ability and retention (EPR) effect, which 
the promise of cancer nanotechnology 
has partially relied on, has proved more 
heterogeneous and unpredictable than 
anticipated. In contrast to the limitations 
of nanoparticles, immune cells are an 
optimal drug delivery vehicle due to their 
ability to cross-navigate the blood and lym-
phatic circulatory system, penetrate the 
blood–brain barrier, the fibrotic exterior 
of a tumor, or other barriers, and actively 
accumulate in diseased regions.[2,3] Com-
bining the benefits of nanoparticle encap-
sulation and stability with the intrinsic 
trafficking, phagocytosis, and secretion 
activity of immune cells may be the best 
combination to achieve therapeutic doses.
Targeted delivery of RNA interference 
(RNAi) therapeutics to the tumor microenvironment has been 
aggressively pursued but is technically challenging.[4,5] Small 
interfering RNA (siRNA) therapeutics are highly effective but 
are currently limited clinically by poor pharmacokinetics and 
can benefit from cell carriers. siRNA therapies can target with 
high precision previously “undruggable” mutations because it 
can knockdown genes post-transcription/pre-translation stage. 
Further, siRNA therapy avoids the possible genomic muta-
tions associated with DNA therapies.[5] Because naked siRNA 
has a short half-life in circulation, strategies to overcome this 
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1. Introduction
Nanotechnology has been transformative for the efficacy of 
cancer treatment. Through the precise engineering of nano-
particles, one can increase drug circulation half-life, synergize 
combinatorial therapies, and deliver insoluble drugs. However, 
nanoparticles can have relatively poor tumor distribution, poor 
endosomal escape. The development of new particles alone 
may not always overcome the barrier to achieving efficient drug 
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limitation involve nanoparticle delivery[6–8] or structural modi-
fication of the siRNA itself.[9] However, these limitations of 
siRNA pharmacokinetics do not impede their direct delivery 
to the eye, lung, and liver.[7,10] One recent example is Patisiran 
(Alnylam), an RNAi therapeutic that targets a protein produced 
in the liver, has completed Phase 3 trials and is the first RNAi 
therapeutic to receive FDA approval.[11] Still, many cancer-
related RNAi therapies are limited by effective transport into 
solid tumors and endosomal escape once inside the cell.
Cationic siRNA lipoplexes are beneficial packaging systems 
for nonviral siRNA delivery.[12–14] Cationic lipids form complexes 
with negatively charged siRNA via electrostatic interaction.[15,16] 
Optimization of the complex formation parameters (such as 
lipid composition, ratio to siRNA, mixing temperature, etc.) has 
led to efficient delivery into the cell and subsequent endosomal 
escape in vitro.[17,18] However, due to cationic lipid-induced tox-
icity, inflammation, and poor distribution profiles, in vivo suc-
cess of lipoplexes has been limited.
Using immune cells as drug delivery vehicles has been well 
published.[19–21] Immune cells have been used as broad func-
tional carriers, where the surface is coated with therapeutic 
nanoparticles. This method has been employed to target white 
blood cells within the bloodstream,[22] T lymphocytes,[23] natural 
killer cells[24] among others. Red blood cells have been used to 
carry drugs[25] and have been very useful in delivering drugs to 
blood clots and injury sites because of their long lifespan and 
large quantity. The methods previously described involve incor-
poration of nanoparticles to the surface of the immune cells 
and rely passively on the migratory properties of the immune 
cells. However, another type of packaging which requires a 
functional interaction between the nanoparticle cargo and the 
immune cells. This describes cells such as macrophages that 
can internalize their delivery cargo and release at the disease 
site. Macrophages in other contexts have been shown to transfer 
oligonucleotides to surrounding cells.[26,27] Our previous work 
has shown that macrophages can horizontally transfer proteins 
and DNA into neurons,[28] muscle cells,[29] and even immune 
cells in distal organs.[30]
There are two central reasons why macrophages are ideal 
carriers for delivery into solid tumors. First, macrophages 
penetrate and accumulate in tumors at significant numbers 
throughout tumor progression. This accumulation can account 
for 30–50% of the mass of a solid tumor. Many immunothera-
pies centralize T cells; however, there are several reasons why 
this strategy is limiting. It has been well documented that 
T-cells either do not localize or cannot survive the tumor sup-
pressive environment.[31,32] While T-cell therapies have shown 
success in blood cancers such as leukemia and non-Hodgkin’s 
lymphoma, these therapies leave out 80% of the patient popu-
lation who present with solid tumors. Even within blood can-
cers, only subset of those patients have sufficient numbers of 
T cells that can be harvested.[33] Since macrophages participate 
in antigen presentation, targeting macrophages may also have 
the benefit of priming the solid tumor environment for T-cell 
infiltration. Second, macrophages phagocytose and secrete oli-
gonucleotides and proteins into the surrounding environment. 
Intercellular communication can modulate the micro or local 
environment via secretion of cytokines and nucleic acids. How-
ever, it is less well appreciated that macrophages can transfer 
exogenously administered proteins and oligonucleotides. Con-
sidered together, macrophages pose an advantageous and effi-
cient delivery carrier for the tumor microenvironment.
In this study we demonstrate that macrophages horizon-
tally transfer siRNA to surrounding cells in both 2D and 3D 
tumorsphere coculture models. Macrophages that were adop-
tively transferred into mice were also able to penetrate the 
tumor micronenvironment and transmit pharmacologically 
active siRNA to cancer cells in an orthotopic MDA-MB-468 
breast cancer model. This work propels the general use of mac-
rophages for therapeutic delivery and provides a new model for 
drug delivery into solid tumor masses that have been notori-
ously difficult for nanoparticle and other immunotherapies to 
penetrate.
2. Results and Discussion
2.1. Characterization of siRNA Lipoplex Loading into 
Macrophages
To demonstrate proof of transient horizontal transfer, commer-
cially available cationic transfection lipoplexes (GeneSilencer; 
Genlantis) were used to load scrambled, nonhomologous siRNA 
labeled with Cy5.5 (Dharmacon) into the macrophages.[34–36] 
Negative Stain TEM imaging and nanoparticle tracking analysis 
(NTA) revealed condensed siRNA lipoplexes with average sizes 
of 177.2 nm ± 6.6 nm (Figure S1, Supporting Information). 
Imaging flow cytometry (Imagestream, Millipore) analysis con-
firmed that the siRNA lipoplexes were found in intracellular 
vesicles (Figure 1a). There was a heterogeneous distribution 
in the uptake amount of siRNA lipoplexes (Figure 1b). The 
siRNA lipoplexes were fully internalized with less at 0.01% of 
siRNA lipoplex signal colocalizing with the cellular membrane 
(Figure 1c). Following transfection, macrophages were rinsed 
with 1 mg mL−1 heparin sulfate to dissolve noninternalized 
lipoplexes. Measurements of macrophages before and after 
heparin sulfate wash reveal significant differences in the mean 
intensity (Figure 1d). The amount of Cy5.5-labeled-siRNA 
found within the cell was proportional to the initial loading 
concentrations (Figure 1e). The mean intensity data was fit to 
an exponential decay curve to calculate the half-life of siRNA 
within the macrophage populations. The half-life of the siRNA 
in the macrophages increased with higher loading concentra-
tions from 1.3 to 2.1 days for 0.2 to 4 µg respectively. This value 
encapsulates population levels dynamics of siRNA transfer, 
degradation, and cell division—how these factors individually 
affect the half-life of siRNA within macrophages should be fur-
ther studied.
Cytotoxicity due to siRNA loading was measured using the 
CCK-8 assay. The absorbance was higher in the nonloaded mac-
rophages but similar across all three siRNA constructs tested 
(Figure 1f). To observe the effect of siRNA loading on the pro-
liferation, macrophage cell growth was measured over 7 days 
and found no significant differences in growth rate between 
Luciferase siRNA (Luc siRNA) and scrambled siRNA loaded 
macrophages (Figure 1g). Thus, the macrophage prolifera-
tion and survival behavior were unaffected by the loading with 
siRNA lipoplexes. In addition, we characterized siRNA loading 
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into RAW 264.7 cells and found similar trends with regards to 
dosing and cytotoxicity (Figure S2, Supporting Information).
2.2. Luc siRNA Horizontal Transfer from Macrophages Results 
in Knockdown of Luciferase in the Cancer Cells
The transfer of Luc siRNA from macrophages to the cancer 
cells was examined by measuring the reduction of luciferase 
bioluminescence activity in the cancer cells following cocul-
ture with Balb/c RAW 264.7 macrophages transfected with Luc 
siRNA (Figure 2a). As the number of macrophages increased, 
the knockdown also increased (Figure 2b), demonstrating evi-
dence of siRNA transfer that was dependent on the ratio of 
macrophages and the duration of coculture. As a negative con-
trol, macrophages were also transfected with an equal amount 
of scrambled, nonhomologous siRNA (control-siRNA). There 
was no reduction in luciferase activity when cancer cells were 
cocultured with control-siRNA which suggests cancer cell 
death is due to coculture is not likely occurring. Furthermore, 
no difference in luciferase activity (Figure 2c) was noted in 
cancer cells incubated in media harvested from macrophages 
24 h after transfection with either control siRNA or Luc siRNA. 
Interestingly, under conditions of this experiment, the maximal 
knockdown was observed when macrophage to cancer cell ratio 
was higher than 50% (Figure 2d). Since tumor associated mac-
rophages make up to 50% of tumor mass,[37,38] this suggests 
a real potential for macrophages as delivery carriers in cancer 
treatments.
Macrophage horizontal transfer of siRNA was also tested 
using other macrophage cell lines. Knockdown of luciferase 
expression in 3LL Lewis Lung carcinoma cells was replicated 
in human THP-1 macrophages (Figure S3, Supporting Infor-
mation). THP-1 did not monocytes show effective transfer, and 
this may be due to their poor siRNA transfection (Figure S4, 
Supporting Information). Optimization of culture conditions 
and siRNA transfection parameters will be needed to fully test 
monocyte gene transfer. Overall, these results using several 
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Figure 1. Characterization of siRNA loading into IC 21 macrophages. a) Imaging Flow Cytometry (Imagestream) image of IC21 macrophages loaded 
with scrambled siRNA-Cy5.5. Objective 60×; scale bar 7 µm. b) Histogram of the percent of cells with different numbers of compartments (vesicles) 
containing scrambled siRNA-Cy5.5 24 h after transfection. c) Imagestream analysis of degree of internalization of scrambled siRNA-Cy5.5 nanofor-
mulation immediately after macrophage transfection and heparin sulfate wash. d) FACS analysis of mean intensity of macrophages transfected with 
scrambled siRNA-Cy5.5 before and after wash with 1 mg mL−1 heparin sulfate. e) 1 × 106 IC21 macrophages were plated in a 6 well plate transfected with 
varying concentrations of scrambled siRNA-Cy5.5 + 0.2 µg (black); 1 µg (asterisk); 2 µg (grey, triangle), 4 µg (orange, upside-down triangle). Plotted 
lines represent exponential decay fitted curves used to calculate siRNA half-life. FACS analysis of siRNA-Cy5.5 remaining in macrophages up to 6 days 
after loading. f) CCK-8 Cytotoxicity assay 10 × 104 IC21 macrophages were plated into a 96 well plate and loaded with either scrambled siRNA-Cy5.5, 
Luc siRNA, or CIB1-siRNA. g) 10 × 104 IC21 macrophages were plated into a 96 well plate and loaded with either scrambled siRNA-Cy5.5 or GFP siRNA. 
Time-lapse images were taken every 2 h for 7 days and the proliferation (percent of area covered by cells) was analyzed. Statistical analysis done using 
Prism software by one-way ANOVA followed by post hoc Tukey test. c,d) Unpaired t-test for two group comparisons. **p < 0.005; n = 3 for all groups.
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macrophage and cancer cell models support the finding that 
the siRNA is being transferred from the macrophage to the 
cancer cells and suppresses gene expression.
2.3. siRNA Horizontal Transfer Dynamics
The Luc siRNA assay provided a sensitive tool for demonstra-
tion of siRNA transfer from a macrophage donor to a cancer 
cell recipient; however, it was difficult to understand the 
kinetics of this transfer without quantifying cell population 
numbers and the amount of siRNA within each group. There-
fore, a fluorescent coculture model was developed (Figure 3a). 
IC21 macrophages were stably transduced with a nuclear local-
izing red fluorescent protein, NucLight Red (Essen Bioscience) 
lentivirus (IC21-NR) and MDA-MB-231 cancer cells were stably 
transduced to express GFP (MDA-MB-231-GFP). The two cell 
populations remain distinct during coculture evidenced by flow 
cytometry analysis (Figure 3b).
We further characterized our coculture model by investi-
gating the effect of coculture on cell viability on MDA-MB-231 
cells. Using time-lapse fluorescent microscopy, we cocultured 
the human cells with either human THP-1 macrophages, 
C57Bl6 IC-21 macrophages, or Balb/c RAW 264.7 macrophages. 
As a control MDA-MB-231 GFP cells incubated alone. Viability 
was assessed by the increase in GFP signal over time. To deter-
mine whether cytokine signaling from macrophages affected 
the cancer cells growth, MDA-MB-231 GFP cells were incu-
bated with media from the macrophage cells lines. We found 
that while the MDA-MB-231 GFP cells grew best in the con-
trol group, there was no significant difference in proliferation 
among the macrophage conditioned media treated cancer cells 
(Figure S5a, Supporting Information).
MDA-MB-231 GFP cells were also cocultured with human 
with macrophages at a 1:2 ratio comparable to experiments 
within the paper (Figure S5b, Supporting Information). 
There was a statistically significant difference in prolifera-
tion in the coculture experiment between the monoculture 
control and the macrophages cocultures. However, there was 
no significant difference between human or mouse media or 
coculture groups. The difference in proliferation between the 
cancer cell monoculture control and cocultured with mac-
rophages is likely a result of limited surface area upon which 
to grow and nutrient resources—the cocultures had more cells 
(Figure S5c, Supporting Information). We conclude that there 
is an effect on cancer cell growth due resource competition as 
a result of coculturing. Importantly, there are no distinguish-
able effect on viability of culturing human cancer cells with 
mouse macrophages in comparison to culturing with human 
macrophages.
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Figure 2. Macrophage horizontal transfer of Luc siRNA into cancer cells. a) Schematic of siRNA transfer coculture experiment. Balb/c RAW 264.7 
macrophages transfected with 4 µg of Luc siRNA or 4 µg of scrambled siRNA (control siRNA). Twenty-four hours after transfection, macrophages are 
rinsed and cocultured with Balb/c 4T1 breast cancer cells stably expressing Renilla-Luciferase (4T1-RLuc) at varying compositions. b) The luciferase 
activity was measured at different timepoints after coculture incubation and was expressed in relative light units (RLU) normalized by total protein 
content. A composition of 70:30 corresponds to a total composition of 70% cancer cells and 30% macrophages. c) Media removed from RAW 264.7 
macrophages prior to heparin sulfate wash was collected and incubated with 4T1-RLuc cancer cells. RLU µg−1 protein values are calculated and normal-
ized to the 12 h timepoint. d) Percentage of luciferase knockdown calculated for each condition at different time points and graphed as a function of 
the ratio of macrophages to cancer cells at that timepoint. The number of cells at different time points were estimated using macrophage and cancer 
cell doubling times. ANOVA statistical analysis performed with Tukey posttest. ***p < 0.0001; n = 3 for each timepoint.
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IC21-NR macrophages were transfected with two different 
concentrations of a scrambled siRNA tagged with a Cy5.5 fluo-
rescent dye (scrambled siRNA-Cy5.5). Immediately after trans-
fection, macrophages were cocultured with MDA-MB-231-GFP 
cells in a tumorsphere. At various intervals between 1 and 6 
days after tumorsphere initiation, tumorspheres were disag-
gregated into a single cell suspension and analyzed using flow 
cytometry to determine the macrophage and cancer cell frac-
tions containing scrambled siRNA-Cy5.5.
For both macrophage-loading conditions, the percentage of 
cancer cells containing siRNA surpassed that of macrophages 
containing siRNA at around 36 h of coculture. As expected, 
the macrophages loaded with a higher amount of siRNA (2 µg) 
showed a higher overall percentage of siRNA positive cells for 
both the donor and recipient cells. In addition, the percentage 
of cancer cells containing siRNA peaked at 2 days for the 1 µg 
loading condition (Figure 3c) and 4 days for 2 µg loading 
condition (Figure 3d). The overall population of macrophages 
and cancer cells measured at any given time point remained 
relatively constant. IC21-NR macrophages composed 60–80% 
of the cells while MDA-MB-231-GFP cancer cells composed 
20–40% of cells measured (Figure 3e). These data suggest that 
as the initial macrophage loading increased, the transfer of 
siRNA from macrophages to the cancer cells and the retention 
of the siRNA in both cell types also increased.
The knockdown of GFP expression via horizontal transfer of 
GFP-siRNA was investigated by loading IC21-NR macrophages 
with 2 µg GFP-siRNA (Thermofisher) and measuring GFP 
expression in the MDA-231-GFP populations 48 h post cocul-
ture. Macrophages were cocultured with cancer cells in either 
a 1:3 (Figure 3f) or 1:10 (Figure 3g) seeding ratio. There was a 
31% decrease in GFP+ positive cells in the IC21(GFP-siRNA) 
coculture compared negative control coculture (Figure 3f). 
However, at the lower ratio (1:10) there was only an 18% 
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Figure 3. Kinetics of siRNA transfer between macrophages and cancer cells. a) Schematic of the study. b) Flow cytometry separation analysis of mac-
rophages and cancer cells. Plots show (left to right) all measured live cells, single cells, and distinct distribution of MDA-MB-231 GFP cancer cells 
and IC21-NR macrophages. IC21-NR macrophages (1.0 × 106) are transfected with either c) 1 µg or d) 2 µg of scrambled siRNA labeled with Cy5.5. 
Immediately following transfection, the macrophages are rinsed and mixed with MDA-MB-231-GFP cells in rounded, ultralow attachment 96 wells at a 
50:50 cell ratio. Then, the seeded 96 well plates were centrifuged at 1500 × g for 15 min to initiate tumorsphere formation before placing into a 37 °C 
incubator. At different timepoints, the tumorspheres were collected, disaggregated, and analyzed via flow cytometry. c,d) Percentage of macrophage 
(black) and cancer cell (green) populations containing Cy5.5-labeled scrambled siRNA. e) The average percentage of measured cells that were mac-
rophages (black) or cancer cells (green) in the coculture at different timepoints. f,g) IC21-NR macrophages (1.0 × 106) are transfected 2 µg of GFP-
siRNA and cocultured with MDA-MB-231-GFP cells at a ratio of f) 1:3 or g) 1:10. h) IC21-NR macrophages (1.0 × 106) are transfected with 2, 4, or 6 µg 
of GFP-siRNA and cocultured with MDA-231-GFP cells. f–h) The percentage of GFP+ expressing cells were analyzed 48 h after coculture using flow 
cytometry. Statistical analysis is done by unpaired t-test using Prism software: **p < 0.005; ***p < 0.001; n = 3 for each measurement.
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decrease in GFP+ positive cells (Figure 3g). Interestingly, the 
macrophage:cancer cell ratio and the percentage knockdown 
fits within the relationship proposed in (Figure 2d) even though 
the macrophage cell line and target cancer cells are different.
As a point of comparison, MDA-MB-231 cancer cells were 
directly transfected with GFP-siRNA using geneSilencer lipo-
plexes (Figure S6, Supporting Information). The percentage 
of GFP+ cells decreased by 72% using similar loaded condi-
tions to the macrophage transfer experiment (2 µg GFP-siRNA, 
measured 48 h post transfection). While direct transfection was 
more effective, their capacity for in vivo application is limited 
due to toxicity. The ability of macrophages to hone to regions 
of inflammation, carry and transfer function siRNA is a notable 
combination.
To test the role of initial loading, we kept the coculture 
ratio at 1:10 but varied the initial amount from 2 to 6 µg of 
GFP-siRNA (Figure 3h). While there were decreases in the 
percentage of GFP+ cells (13% and 6% for 4 and 6 µg, respec-
tively), they did not perform significantly better than 2 µg. 
This may be due to the saturation of the macrophage loading 
capacity which plateaus at 2 µg using the geneSilencer transfec-
tion system (Figure S7, Supporting Information). In the future 
we might specifically consider technologies that can increase 
loading in macrophages such as using mannose-receptor tar-
geted polyplexes.
2.4. Macrophages Loaded with CIB1-siRNA Inhibit Growth  
of MDA-MB-468 Cells
Next, we examined whether the transfer of siRNA from mac-
rophage to cancer cells could result in a therapeutic anticancer 
effect. Towards this goal, we delivered siRNA to knockdown 
calcium integrin binding protein-1 (CIB1) that is known to pro-
mote survival and proliferation in triple negative breast cancer 
(TNBC) cells via regulation of AKT and EKT activation.[39,40] 
Consistent with previous reports, the human TNBC MDA-
MB-468 cells displayed a dose-dependent decrease in the cell 
survival after transfection with CIB1-siRNA (Figure 4a). In 
contrast, mouse IC21 macrophages were insensitive to CIB1-
siRNA (Figure 4b). Moreover, quantitative real-time poly-
merase chain reaction (qPCR) analysis of the macrophages 
did not show a measurable amount of CIB1 RNA, which made 
them perfectly suitable as a vehicle for the delivery of CIB1-
siRNA to the TNBC cells. IC21 macrophages were transfected 
with CIB1-siRNA and then cocultured MDA-MB-468 cells at a 
1:2 ratio (one macrophage for every 2 cancer cells) in a tum-
orsphere as described above to recapitulate the 3D contact of 
macrophages and cancer cells as seen in vivo. The growth of 
tumorspheres was analyzed by live cell imaging and expressed 
as percentage of growth change (Figure 4c). There was a sig-
nificant reduction in the tumorspheres growth kinetics for the 
groups containing macrophages transfected with CIB1-siRNA 
and those transfected with control siRNA. During the 4 days 
of coculture the control tumorspheres increased up to 70% 
in confluency whereas the CIB1-siRNA treated tumorspheres 
experienced only a 20% or 30% change in growth (Figure 4d). 
There was no significant difference between the two initial 
loading concentrations of CIB1-siRNA (2 or 4 µg) on the effect 
on tumorsphere growth, albeit the higher CIB1-siRNA concen-
tration trended toward increased growth inhibition. Overall 
however, both CIB1-siRNA groups show smaller and more 
compact tumorspheres than control siRNA groups 4 days post 
coincubation.
In a separate study, tumorspheres were analyzed for changes 
in mRNA expression of CIB1 and KI67, a marker of human 
cell proliferation. Coculture of MDA-MB-468 breast cancer cells 
with IC21 macrophages transfected with varying amounts of 
CIB1-siRNA resulted in significant decreases in CIB1 and KI67 
mRNA expression (Figure 4e). In contrast, MDA-MB-231 cells 
were not sensitive to CIB1 signaling.[39,40] Coculture of MDA-
MB-231 cells with IC21 macrophages transfected with CIB1-
siRNA did not significantly reduce expression of CIB1 or KI67 
(Figure 4f). To test the effect of gene transfer on nornal cells, 
MCF10a (human epithelial breast cells) were also cocultured 
with IC21 macrophages transfected with 2 µg CIB1-siRNA. No 
significant differences in CIB1 or KI67 mRNA expression were 
found (Figure S8, Supporting Information).
2.5. Macrophage Activation Facilitates Horizontal Transfer  
of siRNA
Because macrophages change their functionality based on 
local external stimuli, it was important to investigate whether 
activation informs macrophage horizontal gene transfer. Mac-
rophages were activated into three phenotypes, proinflamma-
tory (M1; 1ug LPS), anti-inflammatory (M2; 20 ng mL−1 IL-4), 
or tumor associated macrophages (TAM; cancer conditioned 
media (CCM)). Naïve, unconditioned macrophages (M0) were 
used as a control for all experiments. The activation phenotype 
(Table 1) was characterized by qPCR measurement of mRNA 
expression of relevant genes (Figure S9, Supporting Informa-
tion). Macrophages activated 24 h prior to transfection with 
scrambled siRNA Cy5.5 lipoplexes were found to have dif-
ferential uptake activity (Figure 5a). M0 and M1 activated 
macrophages contained comparable percentages of siRNA 
Cy5.5+ cells, however M1 macrophages had a higher mean 
intensity indicating that M1 macrophages endocytosed a larger 
amount of siRNA lipoplexes (Figure S6, Supporting Informa-
tion). In contrast, both M2 and CCM activated macrophages 
endocytosed fewer siRNA lipoplexes than M0 and M1.
The effect of macrophage activation on intracellular traf-
ficking of siRNA lipoplexes by transfecting M0 macrophages 
with siRNA lipoplexes and exposing to activation conditions 
for 24 h before analysis. The M1 macrophages contained 
56% less siRNA lipoplexes in comparison to naïve, M0 mac-
rophages (Figure 5b). Interestingly, M2 activated macrophages 
contained 67% less while CCM macrophages contain 82% 
less (Figure 5b). To elucidate the fate of the siRNA lipoplexes, 
lysosomal activity was measured. Colocalization studies 
using imaging flow cytometry revealed that siRNA lipoplexes 
M1 activated macrophages had higher colocalization with 
Lysotracker Green (Invitrogen) (Figure 5i) than CCM activated 
macrophages. Quantified over 10 000 cells for each condition 
(Figure 5h), M1 macrophages had on average a colocalization 
score of 2.5 in comparison to CCM (≈1.2). Moreover, CCM acti-
vated macrophages secreted higher amounts of exosomes in 
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comparison to M1 activated macrophages (Figure 5g). Finally, 
macrophages activated into an M2 phenotype and loaded with 
siRNA lipoplexes exhibited a higher degree of siRNA transfer 
than M1 macrophages to both MDA-MB-231-Luc human breast 
cancer cells (Figure 5d) and 3LL-Luc murine Lewis lung carci-
noma cells (Figure 5e).
To test the effect of the lipoplex in gene transfer, mac-
rophages were transfected via electroporation. IC21 mac-
rophages were electroporated with 2 µg of scrambled siRNA 
Cy5.5 and exposed to activating media for 24 h before analysis 
with flow cytometry (Figure 5c). Results show a similar trend 
to lipoplex-transfected macrophages in (Figure 5b) although 
there was a higher percentage of cells containing siRNA Cy5.5 
in all groups. In addition, IC21 macrophages electroporated 
with 2 µg of Luc siRNA and cocultured with 3LL-Luc cancer 
cells demonstrated similar trends in knockdown of luciferase 
activity (Figure 5f). This suggests that the lipoplex may affect 
intracellular trafficking but that macrophage horizontal gene 
transfer is also linked to the activation phenotype of the 
macrophage.
2.6. Horizontal Transfer Facilitated via Rab  
27a Recycling Pathway
Because of the finding of enhanced exosomal secretion in 
M2-activated macrophages, exosomal trafficking pathways 
were investigated. Rab27a is a trafficking protein that regulates 
the intracellular exosome secretion pathway (Figure 6a).[41,42] 
We stably transduced IC21 and RAW 264.7 macrophages to 
express Rab27a-shRNA. Western blot analysis confirms knock-
down of Rab27a protein expression in the knockout cell line 
Adv. Sci. 2019, 6, 1900582
Figure 4. Macrophages loaded with CIB1-siRNA results in decreased growth of breast cancer cells. a) MDA-MB-468 breast cancer cells. b) IC21 
macrophages cells were transfected with 0–60 µg CIB1-siRNA. Forty-eight hours after transfection cell cytotoxicity was measured using CCK-8 assay. 
IC21 macrophages were transfected with either 2 or 4 µg CIB1-siRNA or 2 µg scram-siRNA and cocultured at a ratio of 1:2 IC21 macrophage:MDA-
MB-468 cells in a tumorsphere formation. c) Time-lapse brightfield images of tumorspheres in coculture containing MDA-MB-468 cancer cells and 
IC21 macrophages loaded with either CIB1-siRNA or scrambled siRNA at Day 1 (top) and Day 4 (bottom). d) The percentage of tumorspheres growth 
change was quantified. e,f) IC21 macrophages were transfected with either 0.2, 2, or 4 µg CIB1-siRNA cocultured a ratio of 1:2 with e) MDA-MB-468 
or f) MDA-MD-231 cells in a tumorsphere formation. e,f) Changes in mRNA expression of CIB1 and Ki67 after 4 days of coculture. One-way ANOVA 
analysis was performed with Tukey post hoc test: **p < 0.01; ***p < 0.001; n = 3 for all samples.
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(Figure 6b,c). IC21 and RAW 264.7 cell lines were transfected 
with 2 µg of scrambled siRNA Cy5.5 lipoplexes and measured 
for the mean intensity 24 h later. In both cell types, Rab27a- 
macrophages retained more siRNA than wt macrophages 
(Figure 6d,e) and exhibited a narrower spectral distribution of 
the mean intensity macrophage (Figure 6f). Moreover, there 
were fewer exosomes isolated over a 24 h period from RAW 
264.7 (Figure 6h) and IC 21 Rab27a- (Figure 6g) macrophages in 
comparison to IC21 wt. Rab27a- macrophages transfected with 
2 µg of Luc siRNA and cocultured with 3LL-Luc (Figure 6i,j). 
Neither cell type cancer cells had a significant knockdown in 
luciferase activity after 48 h.
In Figure 5, it was demonstrated that macrophage activation 
enhanced siRNA transfer. A possible mechanism is through 
enhanced exosomal secretion under M2, anti-inflammatory 
macrophage activation, particularly when exposed to cancer 
conditioned media. To test this hypothesis, RAW 264.7 wt mac-
rophages were transfected with Luc siRNA and rinsed with hep-
arin sulfate to remove remaining extracellular lipoplexes. Mac-
rophages were then incubated in either nonconditioned serum 
free media (SFM) or cancer conditioned serum free media 
(SFM) for 24 h. As a control, nontransfected macrophages were 
incubated in nonconditioned serum free media. Exosomes 
were isolated from the media via polyethylene glycol (PEG) pre-
cipitation, collected in 100 µL of DMEM. Twenty microliters of 
exosomal solution was incubated with 3LL-Luc cells. After incu-
bation, we found that there was decreased luciferase activity in 
the SFM and CCM-SFM exosome treated groups in compar-
ison to the control group (Figure 6k). Moreover, the CCM-SFM 
group had 23% lower luciferase activity than the SFM group, 
suggesting higher efficacy. Quantification of the exosomes 
reveal that CCM-SFM had a higher concentration of exosomes 
than the SFM or control groups (Figure 6l). Taken altogether, 
this strongly suggests that exosomal secretion via M2 activation 
is involved with gene transfer.
2.7. CIB1-siRNA Loaded IC21 Macrophages Infiltrate  
and Transfer siRNA into MDA-MB-468 Tumors
Finally, macrophage horizontal transfer of siRNA was tested 
in an in vivo mammary tumor model. IC21 macrophages 
were used in the in vivo model because the kinetics of siRNA 
transfer has already been well characterized in the previous 
in vitro models. There is no evidence that the macrophages 
themselves cause cytotoxicity to cells in our coculture experi-
ments. In addition, the CIB1-siRNA construct has already been 
validated and characterized to decrease MDA-MB-468 tumor 
growth in nude animal models in previous literature.[39,40] 
Moreover, previous preclinical studies have delivered mouse 
macrophages in conjunction with nude mouse models inocu-
lated with human cancer cells.[43,44] We used of the macrophage 
and human cancer cell lines used in the in vitro tumorsphere 
assays in (Figure 4) in the paper.
MDA-MB-468 cells were orthotopically implanted into nude 
mice and monitored weekly. At 5 weeks, mice were injected 
with naïve, non-activated IC21 macrophages labeled with 
Nuclight Red (IC21-NR), a nuclear localizing red protein that 
allows distinction between native and adoptively transferred 
macrophages. Mice were sacrificed 24 h after injection and 
the primary tumors were resected and weighed before diges-
tion. Flow cytometry analysis of digested tumor cells positively 
confirms an infiltration of IC21-NR macrophage into the tumor 
(Figure 7a). Further analysis shows a correlation between the 
size of the tumor and the percentage of IC21-NR macrophage 
infiltration. Similar to the experimental scheme in (Figure 2), 
the percentage of CIB1-siRNA-Cy5.5 remaining within both 
the infiltrated IC21-NR macrophages and the host tumor was 
calculated. Impressively, 2% of the tumor cells were CIB1-
siRNA-Cy5.5+ (Figure 7b). Of the tumor infiltrated IC21-NR 
macrophages 4% retained CIB1-siRNA-Cy5.5+, which is slightly 
lower than the 24 h time point in in vitro tumorsphere models 
(Figure 3d).
3. Conclusions
In this paper, we demonstrated that macrophages can horizon-
tally transfer siRNA to tumor cells. We developed two reporter-
gene based models to characterize the pharmacodynamic 
siRNA transfer between macrophage and cancer cell popu-
lations. In addition, we confirmed macrophages horizontal 
transfer of siRNA can result in therapeutic effect as evidenced 
by decreased tumorsphere growth via delivery of CIB1-siRNA 
to MDA-MB-468 breast cancer cells. Altogether, our data sug-
gests that macrophages can deliver siRNA and that the delivery 
can be titrated through the initial amount loaded into mac-
rophages and the ratio of macrophages. These models can be 
used in future studies to optimize the therapeutic effect of mac-
rophage delivery systems.
There are several reasons that make macrophage horizontal 
gene transfer very worthy for exploring as a strategy in cancer 
gene therapy. First, the high ratio of macrophages might be 
achievable in the tumor environment where macrophages 
reportedly reside in high ratios.[45] Second, while this technique 
may not be beneficial for delivering a therapeutic that required 
Adv. Sci. 2019, 6, 1900582
Table 1. Primers used in qPCR experiments. Chart of primers used in 
qPCR reactions (M denotes a mouse specific gene; H denotes a human 
specific gene; F forward; R reverse).
18s F TGTGCCGCTAGAGGTGAAATT
18 R TGGCAAATGCTTTCGCTTT
M Arg1 F CTCCAAGCCAAAGTCCTTAGAG
M Arg1R GGAGCTGTCATTAGGGACATCA
M Mrc2 F TCTCCCGGAACCGACTCTTC
M Mrc2 R AACTGGTCCCCTAGTGTACGA
M Nos2 F ACATCGACCCGTCCACAGTAT
M Nos2 R CAGAGGGGTAGGCTTGTCTC
M CD163 F GGTGGACACAGAATGGTTCTTC
M CD163 R CCAGGAGCGTTAGTGACAGC
M TNFA F CGTCTCGCAACCTACAAGCA
M TNFA R GGTATCCGACTCTACCCTTGG
H CIB1 F ACATCAAGTCCCATTATGCCTTC
H CIB1 R GACGCACTAAGCCGTGTGT
H Ki67 F GGGCCAATCCTGTCGCTTAAT
H KI 67 R GTTATGCGCTTGCGAACCT
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near universal transfer for effect (i.e., p53, KRAS), it would 
be useful for delivering therapeutics that can alter the tumor 
microenvironment (i.e., matrix metalloproteinases, TBF-beta). 
Third, the number of macrophages needed can be reduced via 
optimization of the macrophage transfection conditions. If it is 
possible to load more siRNA into the macrophage and control 
its release, then macrophage horizontal gene transfer becomes 
a very valuable delivery mechanism. Finally, the mere finding 
of gene transfers presents a revolutionarily new strategy for 
gene delivery into solid tumors, an environment that is difficult 
Adv. Sci. 2019, 6, 1900582
Figure 5. Macrophage activation facilitates horizontal transfer of siRNA. Percentage of IC21 macrophage containing scrambled siRNA Cy5.5 when 
conditioned with activation media a) 24 h before, or b) 24 h after siRNA lipoplex transfection (SLP), or c) 24 h after transfection using electropora-
tion (EP). Percentages of scrambled siRNA Cy5.5 remaining 24 h a) post transfection or b,c) post conditioning with activation media are presented. 
Luciferase expression in d) MDA-231-Luc or e,f) 3LL-Luc cells after coculture of these cells for 48 h with activated macrophages carrying Luc siRNA. 
Macrophages were first activated for 24 h, then transfected with 2 µg Luc siRNA using either d,e) siRNA lipoplex or f) electroporation, and immedi-
ately after transfection cocultured with Luciferase-expressing cancer cells for 48 hours. Luciferase activity was expressed in relative light units (RLU). 
d–f) Control represents naïve unconditioned macrophages transfected with scrambled siRNA and cocultured with cancer cells. g) Quantification of 
exosomes collected over 24 hours from M1 (LPS) and M2 (CCM) activated macrophages. h) Macrophages transfected using scrambled siRNA Cy5.5 
lipoplex were conditioned with activation media for 24 h and stained with Lysotracker Green. Imagestream colocalization analysis of siRNA and 
Lysotracker Green between M1 (LPS) and M2 (CCM) activated macrophages. i) Quantification of degree of colocalization histogram. In all panels 
one-way ANOVA analysis was performed with Tukey post hoc test: **p < 0.01, ***p < 0.001; n = 3 for each group.
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to infiltrate. It could also be a unique future strategy for drug 
delivery to metastatic sites, as inflamed monocytes and mac-
rophages form premetastatic niche in the metastatic process.[46]
Our study found that M2 macrophages were better at trans-
ferring siRNA to cancer cells, due to the role macrophage acti-
vation plays a significant role in siRNA uptake and release. 
Adv. Sci. 2019, 6, 1900582
Figure 6. Horizontal transfer facilitated via Rab27a recycling pathway. a) Schematic of exosomal secretory pathway. b) Western blot and c) quantification 
of Rab27a- protein expression in IC21 wildtype (wt) and Rab27a-shRNA (Rab27a-) stably transduced knockdown cell line. Arithmetic mean intensity 
of scrambled siRNA Cy5.5 remaining in d) RAW 264.7 wt or Rab27a- and e) IC21 wt or IC21 Rab27a- macrophages 24 h after lipoplex transfection. 
f) Histogram of distribution of siRNA Cy5.5 intensity between IC21 wt (red) or IC21 Rab27a- (black) macrophages. Quantification of exosomes collected 
over 24 h from g) IC21 wt or IC21 Rab27a- macrophages. h) RAW 264.7 wt or Rab27a- macrophages. 3LL-Luc cancer cells were cocultured with either 
i) RAW 264.7 wt or Rab27a- or j) IC21 wt or IC21 Rab27a- macrophages that were transfected with Luc siRNA or scrambled siRNA. Bioluminescence 
activity (RLU) was measured 48 h after coculture. k) RAW 264.7 macrophages were transfected with Luc siRNA and incubated nonconditioned serum 
free media (SFM) or cancer conditioned serum free media (CCM-SFM) for 24 h prior to exosome isolation. Exosomes were collected and incubated 
with 3LL-Luc cells. Bioluminescence activity (RLU) was measured 48 h after coculture. l) Quantification of exosomes harvested after macrophages 
were transfected with Luc siRNA. Statistical analysis done using Prism software by Unpaired t-tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001, 
n.s. = nonsignificant; n = 3 for each sample group.
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Macrophages polarized into an M1, proinflammatory pheno-
type exhibited higher uptake of siRNA lipoplexes and high 
lysosomal activity, which directly correlates with the known 
behavior of these macrophages. In contrast, M2, anti-inflam-
matory activated macrophages exhibited lower uptake rates 
of siRNA lipoplexes and lower lysosomal activity. M2 macro-
phages produced more exosomes than M1 macrophages. Taken 
together, this evidence suggests that M2 activated macrophage 
are more efficient at horizontal gene transfer because of lower 
lysosomal degradation and higher exosomal secretion activity. 
The activation dependent role for gene transfer has large impli-
cations for gene delivery into the solid tumor. Macrophages and 
monocytes recruited to the tumors become alternatively polar-
ized to immunosuppressive M2 type.[47] Our findings suggest 
that this may become an additional trigger-release mechanism 
for the horizontal gene transfer from the siRNA preloaded 
macrophages migrating to the tumors (“Trojan horses”) to the 
surrounding tumor cells. Several studies demonstrate that 
nano particle size, shape, and composition can modify mac-
rophage activation.[48] Future studies should explore how the 
design of nanoparticles can modulate macrophage activation in 
vivo.
Today, most clinical approaches to tumor gene delivery are 
limited to direct injections of the nuclei acid to the tumor.[49,50] 
Recently, extracellular vesicles (EVs) or exosomes have attracted 
considerable attention due their ability to target many can-
cers.[51–53] There are several advantages to using macrophages 
as a delivery vehicle in comparison to exosomes. Exosomes can 
be loaded relatively well with proteins,[54–56] but loading with 
nucleic acids is considerably more difficult due to aggregation 
and charge. Purification and isolation of exosomes from pre-
transfected cells is also challenging due to low yield and quality 
control issues.[53,57] But perhaps the best selling advantage is 
that use macrophages can allow for the site-specific localization 
and sustained release of exosomes, which additionally may be 
triggered in tumor environment.
Future work should explore the potential of translating gene 
delivery using macrophages in a clinical setting. Macrophages 
reside in the tissue, however, monocytes, their bloodborne 
precursors are an ideal cell type for cell therapy because they 
are easily harvested from the bloodstream. Monocytes/mac-
rophages present a competitive advantage for delivery into the 
tumor environment because of the high recruitment and pro-
liferation that occurs during tumorigenesis.[2,46,47] Furthermore, 
monocyte based cell therapies already exist in other disease 
contexts and have shown some efficacy.[58,59] Immunogenicity 
must be considered; however it is likely to be similar to other 
types of autologous cell therapies.[60–62]
The implications of macrophage horizontal gene transfer are 
valuable for the macrophage biology community and the gene 
delivery field alike. An appreciation for the contribution of mac-
rophages to disease progression and regeneration processes 
has grown over the last decade. Several studies have shown 
that macrophages can act as drug release “depots.” In as early 
as 2000, liver macrophages (Kupfer cells) were reported to act 
as drug reservoirs for docetaxel nanoparticles.[63] More recent 
studies have shown macrophage slow release with drug from 
nanoparticle engulfment.[64,65] Our study corroborates previous 
reports that macrophages can release engulfed materials but 
also adds to this literature by demonstrating that macrophages 
can also release genes that were artificially loaded. The data 
presented focuses on siRNA, however, it is likely that other 
nucleic acids (i.e., pDNA, mRNA, microRNA) can also be deliv-
ered in this fashion.[29] Moreover, the finding that macrophage 
polarization modulates this release of siRNA inspires the 
design of nanoparticle carriers that can take advantage of this 
mechanism. This establishes a framework for macrophages as 
a cellular theranostic: macrophage activity can be used to study 
Figure 7. Adoptively transferred IC21 macrophage infiltrate MDA-MB-468 tumor and horizontally transfer CIB1-siRNA. Groups of six female nude mice 
were inoculated with MDA-MB-468 human breast cancer cells. Mice were intravenously injected with 1.0 × 106 IC21-NR macrophages transfected with 
1 µg CIB1-siRNA-Cy5.5, five weeks after tumor inoculation. Twenty-four hours later, tumors were resected and digested to quantify percentage of cell 
populations within the tumor. a) FACS analysis of separation of adoptively transferred IC21-NR macrophages (right) and cells found within the tumor 
(left). b) Box plot presents the percentages of adoptively transferred IC21-NR cells from the tumor and the percentage of all remaining cells found 
within the tumor that are positive for CIB1-siRNA Cy5.5. The control represents the tumor cells isolated from control groups that were not adoptively 
transferred with IC21-NR macrophages. The median value of the boxplot is displayed as a line while the top and bottom of the box mark the limits of 
±25% of the variable population. Statistical analysis by unpaired t-test using Prism software: *p < 0.05; n = 5 for each group.
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pharmacokinetics and pharmacodynamics of drug–tumor 
interactions as well as promote the specificity of gene delivery.
4. Experimental Section
Cell Culture: IC21 macrophages were maintained in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 10% fetal bovine 
serum (FBS). RAW 264.7 macrophages were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) media supplemented with 10% 
FBS. Human THP-1 monocytes were cultured in (RPMI 10% FBS. 
THP-1 monocytes were incubated with 20 ng mL−1 phorbol 12-myristate 
13-acetate (PMA; Sigma) in RPMI 10% FBS media overnight to different 
into macrophages.
MDA-MB-231 breast cancer cells were lentivirally transduced to 
express green fluorescent protein (MDA-MB-231-GFP). 4T1 breast 
cancer cells were lentivirally transduced to express renilla luciferase 
(4T1-RLuc). 3LL lung cancer cells were lentivirally transduced to express 
firefly luciferase (3LL-FLuc). All cancer cells lines (MDA-MB-231-GFP/
Fluc, 4T1-RLuc, MDA-MB-468, 3LL-FLuc) were maintained in DMEM 
media supplemented with 10% FBS. All cells were cultured under 
standard cell culture conditions (37° C, 5% CO2).
CCK-8 Assay: CCK-8 assay (Dojindo) was used to measure viability. 
Forty-eight hours after transfection, media was removed from each well 
and replaced with a solution containing 90 µL of DMEM and 10 µL of 
CCK8 solution. CCK8 solution was allowed to incubate for 4 h to allow 
time for reaction to occur. Absorbance was measured at 450 nm using 
Spectromax M5 (Molecular Devices).
siRNA Sequences: Silencer Firefly Luciferase (GL2 + GL3) siRNA is 
directly purchased from ThermoFisher (AM4629). Silencer Negative 
Control siRNA (referred to as control siRNA) is additionally purchased 
from ThermoFisher and used as control in the luciferase and time-
lapse imaging experiments. All other siRNA sequences were custom 
synthesized by Dharmacon Inc. (GE Dharmacon). The nonhomologous 
scrambled siRNA (referred to as siRNA-Cy5.5) sense sequence is 5′ A.A
.U.U.C.U.C.C.G.A.A.C.G.U.G.U.C.A.C.G.U.Cy5^5-3′ 3′. The CIB1-siRNA 
sense sequence is 5′ C.A.G.C.C.U.U.A.G.C.U.U.U.G.A.G.G.A.C.U.U.U.
U.Cy5^5-3′ 3′.
Lipoplex Transfection: C57Bl6 IC21 macrophages or Balb/c RAW 
264.7 macrophages were transfected with siRNA using geneSilencer 
(Genlantis) transfection reagent in serum free media following the 
manufacturer’s protocol. One million cells were seeded in 6 well in 
RPMI media supplemented with 10% FBS (without antibiotic) overnight. 
The following day, the media was replaced with 1 mL of RPMI serum free 
media (SFM). From 0.200 to 4 µg of siRNA was mixed with geneSilencer 
reagents and incubated for 15 min then added to 1 mL RPMI SFM. 
After 4 h of incubation, the transfection media was removed from 
cells and then macrophages were washed once in phosphate-buffered 
saline (PBS) and twice in 1 mg mL−1 heparin sulfate in PBS to remove 
extracellular nanocomplexes. Cells were then removed from the tissue 
culture surface using a disposable tissue scraper. Cells were centrifuged 
at 800 rpm for 5 min to remove cell debris and resuspended in media 
in preparation for cell counting and coculture. Macrophages were either 
harvested 24 h after transfection or immediately after transfection.
Electroporation siRNA Transfection: Macrophages were electroporated 
adhering sample preparation protocols of the Neon Transfection 
System (ThermoFisher Scientific). 10e6 macrophages were resuspended 
with 2 µg siRNA and 100 µL resuspension buffer. Macrophages were 
electroplated using 1700 pulse voltages and 20 pulse width. Immediately 
following electroporation macrophages were placed in warm, prepared 
plates for downstream experiments.
Tumorsphere Formation: For coculture tumorspheres, 5000 
macrophages and 5000 cancer cells were transferred to 96 well ultralow 
attachment plates (Corning) and then aggregated by centrifugation at 
1500 rpm for 15 min. Tumorspheres were cultured in 200 µL of DMEM 
supplemented with 10% FBS at 37 °C and 5% CO2 and 50 µL of fresh 
media was added to the side of each well every 3 days.
Negative Stain TEM: siRNA lipoplex samples were applied onto 
negatively glow-discharged carbon-coated grids (400 mesh, copper grid) 
for 1 min, and excess liquid was removed by blotting with filter paper. 
Freshly prepared 1.5% uranyl formate (pH 5) was added (5 µL) for 
1 min and then blotted. Digital micrographs were collected using JEOL 
JEM 1230 Transmission Electron Microscope operated between 40 and 
120 kV and equipped with 5-axis goniometer stage in X, Y, Z, +/− 45° 
tilt, 360° rotation Gatan Orius SC1000 CCD camera. The images were 
recorded using Gatan Microscopy Suite 3.0 software.
Flow Cytometry: The percentage of macrophages expressing 
siRNA-Cy5.5 was measured using flow cytometry (LSR II Fortessa; 
BD Biosciences). Cells transfected with unlabeled control siRNA were 
measured and used as a baseline for background fluorescence. Fifty 
thousand cells were measured per sample. Analysis of flow cytometry 
data was performed using FCS Express.
ImagestreamX Imaging Flow Cytometry: Flow cytometry analytics 
and fluorescent images of cells were collected using ImagestreamX 
(Millipore). Images were collected at 60× magnification. Ten thousand 
cells minimum were analyzed for each sample. Analysis of cellular 
fluorescence was performed using IDEAS (Millipore) software. 
Specifically, colocalization analysis was done using the bright similarity 
detail algorithm and the number of compartments in individual cells 
was analyzed using the Spot Count algorithm.
Ultracentrifugation Exosome Isolation: Macrophages grown in T175 
flasks were incubated with serum-depleted media for 24 h. The exosomal 
media is collected centrifuged at 1500 × g for 10 min to remove cells 
and large cell debris. The pellet was discarded, and the supernatant was 
centrifuged at 20 000 × g to remove larger debris and intact organelles. 
The resulting supernatant is then centrifuged at 150 000 × g to pellet 
exosomes.[53] The recovery of exosomes was quantified by NTA.
PEG Precipitation Exosome Isolation: Macrophages grown in T175 
flasks were incubated in serum free media for 24 h. Media was collected, 
and exosomes were isolated using gradient centrifugation. In brief, 
the culture supernatants were cleared of cell debris and large vesicles 
by sequential centrifugation at 1500 × g for 10 min and 4600 × g for 
30 min. Supernatant was further filtered using through 0.2 µm syringe 
filters and mixed with 10% PEG overnight. Next, the media/PEG mixture 
was centrifuged at 4600 × g for 1 h to pellet the exosomes. The media 
was removed, the pellet was resuspended in 100 µL 1× PBS buffer, and 
stored at −20 °C until analysis. The recovery of exosomes was quantified 
by NTA.
Breast Tumor Implantation and FACS Tumor Analysis: MDA-MB-
468 (5 × 106 cells) in PBS were mixed 1:1 with matrigel (Corning) and 
injected into the left flank mammary fat pad of 5-week-old female nude 
mice (Jackson Laboratories, Bar Harbor, ME). Mice were injected with 
CIB1-siRNA transfected IC21 macrophages after 5 weeks of tumor 
growth. Tumors were resected 24 h post macrophage injection for 
further analysis for presence of CIB1-siRNA in the tumor. Tumors were 
minced and digested in 0.2% collagenase IV in DMEM at 37 C for 
45 min. The resulting mixtures was strained through a 70 µm filter then 
incubated with ACK lysis buffer to eliminate remaining red blood cells. 
Cells were centrifuged to remove remaining cell debris and resuspended 
in FACS staining buffer before flow cytometry analysis. All animal 
procedures were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee (IACUC).
Bioluminescence Assays: After transfection, transfected macrophages 
were cocultured in 96 well plates with either 4T1-RLuc, MDA-231-Fluc, 
or 3LL-FLuc cancer cell lines. At various time points, the media was 
removed and 30 µL of cell lysis buffer (Promega) was added to the 
plate. The plates were wrapped in parafilm and stored in the freezer 
until measurement. Ten microlieter sample lysis mixture was analyzed 
for bioluminescent activity (Glomax 20/20 Luminometer) using either 
QunatiLuc (Invivogen) for renilla luciferase or Luciferin (Promega) for 
firefly luciferase. Luminescence measurements were normalized using 
measurements of total protein concentration using the BCA Protein 
assay (Thermo Fisher Scientific).
Macrophage Activation: Balb/c RAW 264.7 and C57Bl6 IC21 
macrophages were plated at a density of 1.0 × 106 mL−1 in a 6 well plate 
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in 2 mL of activation media for 24 h. The activation conditions were: M0 
(naïve, RPMI +10% FBS media only), M1 (1 µg mL−1 LPS and 20 ng mL−1 
IFN-γ in RPMI supplemented with 10% FBS), and M2 (20 ng mL−1 IL-4 
and 20 ng mL−1 IL-13 in RPMI supplemented with 10% FBS). CCM is 
media collected from MDA-MB-468 human breast cancer cells. After 
activation, media was changed and replaced with serum-free RPMI in 
preparation for experimentation. Macrophage polarization was validated 
by measuring mRNA expression of genes commonly upregulated 
during activation. M2 activation levels were assessed using CD206 
mannose receptor and Arg1 while M1 activation levels were assessed 
using iNOS, TNFα, and CD86 (Figure S8, Supporting Information). In 
all other experiments if not specified differently the naïve unconditioned 
macrophages were used.
Real-Time PCR: mRNA gene expression was determined using SYBR 
green quantitative real-time PCR (qt-PCR) on cDNA template. cDNA was 
generated from 1000 ng RNA per sample using oligo(dT)12-18 primers 
and iScript cDNA Synthesis Kit (Biorad), according to manufacturer’s 
instructions. Product was amplified with 20 × 10−6 m forward and reverse 
primers of gene of interest and SybrGreen Mastermix (Life Technologies) 
on an Applied Biosystems 7900 real-time PCR. The primer sequences 
for SybrGreen primer sets were listed in the Supporting Information 
(Table 1).
Live Cell Imaging: Tumorsphere time-lapse images were collected 
using the Incucyte (Essen Bioscience), a microscope and incubation 
system that allows for long-term monitoring of live cells. Brightfield 
images were taken at 10× objective every 2 h. For the tumorsphere 
inhibition studies the growth of the tumorspheres was monitored using 
IncuCyte (Essen Bioscience), an incubator and built-in microscope 
live-cell imaging system. IncuCyte software was used to calculate the 
confluence, or percentage of the image covered by the tumorsphere. The 
confluence was used to calculate the percentage growth change over 
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